Craft

Fusion Antibodies

Total Funding

$2.5 M

Revenue

£2.2 M

FY, 2019

Fusion Antibodies Summary

Company Summary

Overview
Fusion Antibodies is a CMO that offers a range of services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up. Fusion provides contract services include... - Antibody Humanization services - Antibody Engineering Services - Antibody sequencing Services - Protein Expression & Purification Services - Monoclonal Antibody services BLAST & Standard - cGMP Services Fusion Therapeutics (a division of Fusion Antibodies) is committed to developing therapeutic antibodies and recombinant proteins to disease specific markers. Fusion Therapeutics is primarily focused on the key areas of oncology and angiogenesis where immunotherapeutic intervention has a proven track record. The company’s genomic mining and proteomic discovery strategy has resulted in the development of a growing pipeline of candidate drugs. Fusion Antibodies have a number of exciting targets undergoing validation with two targets currently in preclinical trials.
Type
Private
Status
Active
Founded
2001
HQ
Belfast, GB | view all locations
Website
http://www.fusionantibodies.com
Cybersecurity rating
Sectors

Key People

  • Simon Douglas

    Simon Douglas, Chairman of the Board

  • Richard Buick

    Richard Buick, Chief Scientific Officer and Board Member

  • Sonya Ferguson

    Sonya Ferguson, Non-Executive Director

    • Colin Walsh

      Colin Walsh, Non-Executive Director

    LocationsView all

    1 location detected

    • Belfast HQ

      United Kingdom

      1 Springbank Road Springbank Industrial Est

    Fusion Antibodies Financials

    Summary Financials

    Revenue (FY, 2019)
    £2.2M
    Gross profit (FY, 2019)
    £804.0K
    Net income (FY, 2019)
    (£1.3M)
    Cash (FY, 2019)
    £2.0M
    EBIT (FY, 2019)
    (£1.5M)

    Footer menu